Roy Baynes, Merck Research Laboratories CMO (file photo)
May 19, 2021 05:00 PM EDTUpdated May 20, 05:01 AM
R&D

#AS­CO21: With Bris­tol My­ers set for its own big LAG-3 up­date at AS­CO, Mer­ck touts ear­ly suc­cess for a po­ten­tial com­peti­tor

Kyle Blankenship

Bris­tol My­ers Squibb is set to be the belle of the ball at this year’s AS­CO with a big late-stage read­out for its an­ti-LAG-3 an­ti­body …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times